【摘要】：背景慢傳輸型便秘(slow transit constipation,STC)是由于結(jié)腸傳輸功能障礙,腸內(nèi)容物滯留所引起的一種常見(jiàn)的功能性便秘類型。臨床癥狀頑固,保守治療效果不佳,手術(shù)切除無(wú)力結(jié)腸是最終的選擇。目前,全結(jié)腸切除回直吻合術(shù)(ileorectal anastomosis,IRA)與次全結(jié)腸切除盲直吻合術(shù)(cecorectal anastomosis,CRA)是外科治療STC應(yīng)用最常用的手術(shù)方式。手術(shù)治療STC盡管取得了較滿意的臨床結(jié)局,但其術(shù)后排便功能及生活質(zhì)量的改善狀況少有報(bào)道。同時(shí),一些術(shù)后出現(xiàn)的頑固性腹瀉、便秘復(fù)發(fā)、粘連性腸梗阻等并發(fā)癥仍是影響手術(shù)治療的負(fù)面因素。然而,國(guó)內(nèi)外相關(guān)研究報(bào)道較少,且多為小樣本回顧性研究。因此,研究STC患者術(shù)后療效、排便功能、生活質(zhì)量對(duì)進(jìn)一步改進(jìn)STC的外科治療具有重要的臨床意義。另外,STC作為一種功能性腸動(dòng)力障礙,手術(shù)治療是內(nèi)科治療失敗后的無(wú)奈選擇,如果能夠闡明其病理生理機(jī)制,對(duì)STC的防治將具有重大的推動(dòng)意義。近年來(lái),有研究報(bào)道腸粘膜感覺(jué)信號(hào)在調(diào)控腸道動(dòng)力方面發(fā)揮重要作用。STC患者臨床上突出地表現(xiàn)為無(wú)便意,及無(wú)主觀排便感覺(jué),結(jié)腸傳輸功能障礙,提示腸粘膜感覺(jué)功能異�？赡茉谄浒l(fā)病機(jī)制中發(fā)揮作用。有研究發(fā)現(xiàn),瞬時(shí)受體電位通道A1(transient receptor potential channel-ankyrin subfamily member 1,TRPA1)是腸嗜鉻細(xì)胞(enterochromaffin cell,ECC)的感受器分子,可感知腸腔內(nèi)物理與化學(xué)信號(hào),介導(dǎo)ECC釋放5-羥色胺(5-hydroxytryptamine,5-HT)調(diào)控腸道動(dòng)力。另有研究結(jié)果表明,瞬時(shí)受體電位通道V1(transient receptor potential channel-vanilloid subfamily member 1,TRPV1)在腸粘膜感覺(jué)神經(jīng)調(diào)控腸動(dòng)力中發(fā)揮重要作用,同時(shí),大量研究發(fā)現(xiàn)TRPA1與TRPV1在諸多神經(jīng)與非神經(jīng)組織上存在協(xié)同作用。那么,TRPA1與TRPV1在STC患者結(jié)腸粘膜表達(dá)是否異常,迄今為止,國(guó)內(nèi)外未見(jiàn)報(bào)道。從腸粘膜感覺(jué)神經(jīng)調(diào)控切入初步探討STC的發(fā)病機(jī)制具有重要意義。目的1、回顧性分析stc患者一般資料,對(duì)患者術(shù)后療效、排便功能及生活質(zhì)量改善狀況進(jìn)行評(píng)估;2、觀察stc患者降結(jié)腸粘膜trpa1、trpv1與5-ht的表達(dá)變化,初步探討其在stc發(fā)病中的作用。方法選取大坪醫(yī)院普通外科中心胃結(jié)直腸肛門外科2007年8月至2015年2月明確診斷stc并行手術(shù)治療患者38例作為研究對(duì)象,成功隨訪29例患者,失訪9例(7例失訪、1例拒絕接受隨訪、1例死于呼吸系統(tǒng)疾病合并呼吸衰竭)。所有研究對(duì)象均通過(guò)胃腸道生活質(zhì)量評(píng)分(gastrointestinalqualityoflifeindex,giqli)、wexner便秘評(píng)分(wexnerconstipation,wc)、wexner大便失禁評(píng)分(wexnerincontinence,wi)及sf-36健康調(diào)查問(wèn)卷(36-itemshort-formhealthsurvey,sf-36)進(jìn)行評(píng)估,分析手術(shù)療效及生活質(zhì)量變化情況。同時(shí),收集大坪醫(yī)院普通外科中心胃結(jié)直腸肛門外科2013年3月至2014年3月收治的10例stc患者手術(shù)切除的降結(jié)腸標(biāo)本為stc組,及2013年12月至2014年5月收治的10例乙狀結(jié)腸癌患者手術(shù)切除的降結(jié)腸標(biāo)本(距腫瘤邊緣10cm以上)為對(duì)照組。采用免疫熒光雙標(biāo)檢測(cè)對(duì)照組結(jié)腸粘膜中trpa1與色氨酸羥化酶(tryptophanhydroxylase,tph)、trpv1與tph表達(dá)情況,免疫組化檢測(cè)兩組trpa1、trpv1與5-ht表達(dá)情況,westernblot檢測(cè)兩組trpa1與trpv1表達(dá)情況。所有納入研究對(duì)象均簽署知情同意書。結(jié)果一、stc患者臨床資料分析及術(shù)后療效評(píng)估1、術(shù)后并發(fā)癥及排便功能:1例患者因呼吸系統(tǒng)疾病合并呼吸衰竭死亡。術(shù)后4例(13.8%)患者出現(xiàn)炎性腸梗阻,保守治療治愈;2例患者術(shù)后出現(xiàn)肺部感染,其中1例為腹腔和肺部感染,這是由于出現(xiàn)了十二指腸瘺,再次手術(shù)修補(bǔ)十二指腸瘺治愈。3例(10.3%)患者出現(xiàn)遠(yuǎn)期并發(fā)癥,其中粘連性腸梗阻2例,再次入院行腸粘黏松解術(shù)治愈;便秘復(fù)發(fā)2例;吻合口狹窄1例。與術(shù)前相比,stc患者術(shù)后3月每周排便次數(shù)即顯著增加(p0.01),術(shù)后排便費(fèi)勁、腹脹及瀉劑使用情況均顯著改善(p0.01),89.7%患者表示手術(shù)對(duì)其健康變化有益;2、wexner失禁評(píng)分:與術(shù)后3月相比,stc患者術(shù)后6月、1-2年及2-7年wi分值均無(wú)統(tǒng)計(jì)學(xué)差異(p0.05);3、wexner便秘評(píng)分:與術(shù)前相比,stc患者術(shù)后3月、6月、1-2年及2-7年wc分值均較術(shù)前顯著改善(p0.01);4、胃腸道生活質(zhì)量評(píng)分:與術(shù)前相比,STC患者術(shù)后3月、6月、1-2年及2-7年GIQLI分值均較術(shù)前顯著改善(P0.01);5、SF-36健康調(diào)查問(wèn)卷:與術(shù)前相比,STC患者術(shù)后1-2年生活質(zhì)量在生理職能、情感職能、軀體疼痛、精力、精神健康、社會(huì)功能及一般健康狀況等7個(gè)方面有顯著改善(P0.05);術(shù)后2-7年生活質(zhì)量在生理職能、情感職能、軀體疼痛、精力及社會(huì)功能方面有顯著改善(P0.05)。二、STC患者降結(jié)腸粘膜TRPA1、TRPV1與5-HT表達(dá)情況1、免疫熒光雙標(biāo)檢測(cè)發(fā)現(xiàn)TRPA1與TPH、TRPV1與TPH在人的結(jié)腸粘膜ECC上共表達(dá);2、免疫組化染色檢測(cè)發(fā)現(xiàn):與對(duì)照組相比,STC組降結(jié)腸粘膜TRPA1與TRPV1表達(dá)水平下調(diào)(P0.05),而5-HT表達(dá)水平上調(diào)(P0.05);3、Western Blot檢測(cè)發(fā)現(xiàn):與對(duì)照組相比,STC組降結(jié)腸粘膜TRPA1與TRPV1表達(dá)水平下調(diào)(P0.05)。結(jié)論1、結(jié)腸全或次全切除手術(shù)治療STC是一個(gè)有效且能被大部分患者所接受的治療方案,它不僅在近期內(nèi)能顯著改善患者的便秘臨床癥狀,而且隨著時(shí)間推移,生活質(zhì)量也有顯著提高;2、TRPA1與TRPV1均在腸ECC上表達(dá),提示TRPA1與TRPV1介導(dǎo)ECC釋放5-HT調(diào)控腸道動(dòng)力;STC降結(jié)腸粘膜TRPA1與TRPV1表達(dá)下調(diào),5-HT表達(dá)上調(diào),提示腸粘膜感覺(jué)信號(hào)傳入障礙可能與STC發(fā)病機(jī)制相關(guān)。
[Abstract]:Background slow transit constipation (slow transit constipation, STC) is a common type of functional constipation caused by colon transmission dysfunction and retention of intestinal contents. Clinical symptoms are stubborn, conservative treatment is not effective, surgical removal of the colon is the ultimate choice. Currently, total colectomy and direct anastomosis (ileorectal anastom) Osis, IRA) and subtotal colectomy blind direct anastomosis (cecorectal anastomosis, CRA) is the most commonly used surgical method for the surgical treatment of STC. Although the surgical treatment of STC has achieved a satisfactory clinical outcome, the postoperative defecation function and the improvement of the quality of life are rarely reported. At the same time, some of the postoperative intractable diarrhea and constipation are recovered. Complications such as hair and adhesive ileus are still the negative factors affecting the surgical treatment. However, there are few related reports at home and abroad, and most of them are small sample retrospective studies. Therefore, the study of postoperative curative effect, defecation function and quality of life of STC patients has important clinical significance for the further improvement of the surgical treatment of STC. In addition, STC is a kind of work. Dysfunctional intestinal motility disorder, surgical treatment is a helpless choice after internal medical treatment failure. If it can clarify its pathophysiological mechanism, it will have great significance for the prevention and control of STC. In recent years, there has been a research report that intestinal mucosal sensory signals play an important role in regulating intestinal motility, and.STC patients are clinically prominent in clinical. It is found that the transient receptor potential channel A1 (transient receptor potential channel-ankyrin subfamily member 1, TRPA1) is a receptor molecule of intestinal chromaffin cells (enterochromaffin cell, ECC). We can perceive the physical and chemical signals in the intestinal cavity and mediate the release of 5- hydroxytryptamine (5-hydroxytryptamine, 5-HT) by ECC to regulate intestinal motility. The results show that the instantaneous receptor potential channel V1 (transient receptor potential channel-vanilloid subfamily member 1, TRPV1) plays an important role in intestinal motility in the intestinal mucosa. At the same time, a large number of studies have found that there is a synergistic effect between TRPA1 and TRPV1 in many nerve and non nerve tissue. Then, the expression of TRPA1 and TRPV1 in the colon mucosa of STC patients is abnormal, so far, no reports have been reported at home and abroad. It is of great significance to explore the pathogenesis of STC from the regulation of the sensory nerve of the intestinal mucosa. 1 The general data of STC patients were evaluated for postoperative curative effect, defecation function and improvement of quality of life. 2, the changes in the expression of TRPA1, TRPV1 and 5-HT in the descending colon mucosa of patients with STC were observed, and their role in the pathogenesis of STC was preliminarily discussed. Methods the cardiac and gastric colorectal anus surgery in Daping Hospital was selected from August 2007 to February 2015. 38 patients were treated with STC, 29 patients were followed up, 9 cases were lost (7 cases were lost, 1 refused to follow up, 1 died of respiratory failure with respiratory failure). All the subjects were evaluated by gastrointestinalqualityoflifeindex (GIQLI) and Wexner constipation score (wexnercon Stipation, WC), Wexner (wexnerincontinence, WI) and SF-36 Health Questionnaire (36-itemshort-formhealthsurvey, SF-36) to evaluate the effect and quality of life. At the same time, 10 cases of STC patients in the general surgical center of Daping Hospital were collected from March 2013 to March 2014. The resected specimens of descending colon were in group STC, and 10 cases of colon cancer patients treated from December 2013 to May 2014 were treated with surgical resection of the descending colon (above the tumor margin 10cm) as the control group. The TRPA1 and tryptophan hydroxylase (tryptophanhydroxylase, TPH), TRPV1 and TPH in the colon mucosa of the control group were detected by double immunofluorescence The expression of two groups of TRPA1, TRPV1 and 5-HT were detected by immunohistochemistry, and the expression of TRPA1 and TRPV1 in two groups was detected by Westernblot. All the subjects included in the study signed the informed consent. Results 1, the analysis of clinical data and postoperative efficacy assessment of STC patients 1, postoperative complications and defecation function: 1 patients were associated respiratory failure due to respiratory diseases. After operation, 4 cases (13.8%) had inflammatory bowel obstruction, conservative treatment and 2 cases of postoperative pulmonary infection, including 1 cases of abdominal and pulmonary infection, which was due to the appearance of duodenal fistula, and reoperation of duodenal fistula to cure.3 (10.3%) patients with long-term complications, of which 2 cases of adhesive ileus were re entered. There were 2 cases of constipation, 2 cases of constipation and 1 cases of anastomotic stenosis. Compared with preoperative, the number of defecation in STC patients increased significantly (P0.01) in March, postoperative defecation was hard, abdominal distention and laxative use were significantly improved (P0.01), and 89.7% patients were beneficial to their health changes; 2, Wexner incontinence score: 3 month postoperatively. STC patients had no statistically significant difference (P0.05), 3, and Wexner constipation scores in June, 1-2 and 2-7 years postoperatively. Compared with preoperative, STC patients were significantly improved in March, June, 1-2 and 2-7 years than before operation (P0.01); 4, GI quality score: compared with preoperative, STC patients were compared with surgery in March, June, 1-2 and 2-7 years. Pre significant improvement (P0.01); 5, SF-36 Health Questionnaire: compared with preoperative, the quality of life in 1-2 years after operation in STC patients was significantly improved in 7 aspects of physiological function, emotional function, body pain, energy, mental health, social function and general health status (P0.05), and the quality of life after 2-7 years was in physiological function, emotional function, somatic pain, and essence. There was a significant improvement in the force and social function (P0.05). Two, the expression of TRPA1, TRPV1 and 5-HT in the descending colon mucosa of STC patients was 1. The double immunofluorescence double labeling detected the expression of TRPA1 and TPH, TRPV1 and TPH were co expressed on the colon mucosa of the human colon mucous membrane; 2, immunohistochemical staining found that the lower colon mucosa TRPA1 and expression level of STC group were compared with those in the control group. (P0.05), and 5-HT expression level up (P0.05); 3, Western Blot detection found that compared with the control group, the TRPA1 and TRPV1 expression level of the colon mucosa decreased (P0.05) in the STC group. Conclusion 1, full or subtotal colectomy for STC is an effective and acceptable treatment for most patients. It can not only be significantly improved in the near future. The clinical symptoms of constipation and the quality of life improved significantly over time; 2, both TRPA1 and TRPV1 were expressed on the intestinal ECC, suggesting that TRPA1 and TRPV1 mediated ECC release 5-HT to regulate intestinal motility; the expression of TRPA1 and TRPV1 in the mucosa of STC descending colon mucosa was down regulated, and 5-HT expression was up regulated, suggesting that the sensory afferent disorder in intestinal mucosa may be associated with STC pathogenesis. The system is related.
【學(xué)位授予單位】：第三軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R656.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 任延玉;結(jié)腸粘膜下腫瘤:一種以放射學(xué)表現(xiàn)特點(diǎn)為依據(jù)的新分類[J];國(guó)外醫(yī)學(xué).外科學(xué)分冊(cè);1993年05期

2 萬(wàn)田謨;周丹;姜泊;潘德壽;劉思德;;結(jié)腸粘膜染色的臨床應(yīng)用[J];現(xiàn)代消化及介入診療;2001年02期

3 竹森弘光;王治榮;;結(jié)腸粘膜的免疫機(jī)理[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));1984年01期

4 唐慧強(qiáng);溫步優(yōu);羅莉;;結(jié)腸粘膜染色對(duì)炎癥性腸病及結(jié)腸腫瘤的診斷價(jià)值[J];廣西醫(yī)學(xué);1985年02期

5 徐在和;;全結(jié)腸粘膜下脂肪瘤病一例報(bào)告[J];南京醫(yī)學(xué)院學(xué)報(bào);1987年01期

6 張新華,馬恒輝,周志韶;結(jié)腸粘膜黑變病1例報(bào)告[J];江蘇醫(yī)藥;1993年08期

7 虞功清,鄭筱雯,鄒偉民,趙莉,祝金泉,余揚(yáng)帆;腸易激綜合征患者結(jié)腸粘膜細(xì)胞超微結(jié)構(gòu)的研究[J];電子顯微學(xué)報(bào);2005年05期

8 魯澤清;掃描電鏡研究大腸癌患者結(jié)腸粘膜的超微結(jié)構(gòu)改變[J];國(guó)外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));1982年02期

9 夏冰;于皆平;;潰瘍性結(jié)腸炎模型的結(jié)腸粘膜酶活性的研究(摘要)[J];臨床消化病雜志;1990年02期

10 霍麗娟，，徐大毅;肝硬化門脈高壓病人及大鼠結(jié)腸粘膜的光電鏡觀察[J];中華消化雜志;1996年06期

相關(guān)會(huì)議論文 前10條

1 鄧輝;鐘白云;劉蔚東;馮斯斯;;亞健康便秘人群結(jié)腸粘膜蛋白質(zhì)組的篩選與鑒定[A];中華醫(yī)學(xué)會(huì)第九次全國(guó)檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)會(huì)議暨中國(guó)醫(yī)院協(xié)會(huì)臨床檢驗(yàn)管理專業(yè)委員會(huì)第六屆全國(guó)臨床檢驗(yàn)實(shí)驗(yàn)室管理學(xué)術(shù)會(huì)議論文匯編[C];2011年

2 張尚華;程進(jìn)明;;健腸飲治療慢性非特異性潰瘍性結(jié)腸炎42例總結(jié)[A];第七次全國(guó)中西醫(yī)結(jié)合虛證與老年病學(xué)術(shù)會(huì)議論文摘要集[C];2003年

3 徐敬東;王文;李利生;郭華;朱進(jìn)霞;;粘膜下神經(jīng)叢參與大黃素促進(jìn)大鼠結(jié)腸粘膜陰離子分泌的機(jī)制研究[A];2008年神經(jīng)內(nèi)分泌暨神經(jīng)免疫內(nèi)分泌學(xué)術(shù)研討會(huì)論文摘要匯編[C];2008年

4 王斌;段相林;張宏磊;李紀(jì)標(biāo);邵素霞;安迎春;萬(wàn)五星;;酒精對(duì)小鼠結(jié)腸粘膜表面結(jié)構(gòu)影響的SEM觀察[A];第九次全國(guó)電子顯微學(xué)會(huì)議論文摘要集（Ⅰ）[C];1996年

5 張書義;劉穎;李靜懷;;慢性結(jié)腸炎辨證分型與內(nèi)鏡下結(jié)腸粘膜病理改變關(guān)系初探[A];中西醫(yī)結(jié)合肛腸病研究新進(jìn)展[C];2000年

6 張聲生;郭前坤;汪正芳;陳劍明;吳震宇;李萍;;肝健脾方對(duì)腹瀉型腸易激綜合征模型大鼠結(jié)腸粘膜多巴胺信號(hào)通路離子轉(zhuǎn)運(yùn)的影響[A];中華中醫(yī)藥學(xué)會(huì)脾胃病分會(huì)第二十四次全國(guó)脾胃病學(xué)術(shù)交流會(huì)論文匯編[C];2012年

7 王臻楠;唐志鵬;馬貴同;;清腸栓調(diào)節(jié)TNBS誘導(dǎo)結(jié)腸炎大鼠結(jié)腸粘膜細(xì)胞增殖的研究[A];中華中醫(yī)藥學(xué)會(huì)脾胃病分會(huì)第十八次學(xué)術(shù)交流會(huì)論文匯編[C];2006年

8 杜群;李紅;王汝俊;李燕;巫燕莉;;潰結(jié)靈對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸粘膜Toll樣受體2、4蛋白水平和NF-κB活性的作用[A];第二十次全國(guó)中西醫(yī)結(jié)合消化系統(tǒng)疾病學(xué)術(shù)會(huì)議暨消化疾病診治進(jìn)展學(xué)習(xí)班論文匯編[C];2008年

9 杜群;吳秀美;王汝俊;李燕舞;巫燕莉;;實(shí)時(shí)定量PCR法檢測(cè)潰結(jié)靈對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸粘膜IκB-α基因表達(dá)的作用[A];第二十二屆全國(guó)中西醫(yī)結(jié)合消化系統(tǒng)疾病學(xué)術(shù)會(huì)議暨消化疾病診治進(jìn)展學(xué)習(xí)班論文匯編[C];2010年

10 李燕舞;黃秋凌;王汝俊;;潰結(jié)靈對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸粘膜pMEK1/2、pERK1/2蛋白水平動(dòng)態(tài)變化的影響[A];第十一屆全國(guó)中藥藥理學(xué)術(shù)大會(huì)論文摘要[C];2010年

相關(guān)博士學(xué)位論文 前2條

1 李紅;潰結(jié)靈對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸粘膜TLRs/NF-κB通路的作用[D];廣州中醫(yī)藥大學(xué);2007年

2 宋寧;潰結(jié)靈對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸粘膜ITF表達(dá)及MEK/ERK通路的影響[D];廣州中醫(yī)藥大學(xué);2008年

相關(guān)碩士學(xué)位論文 前10條

1 田躍;慢傳輸型便秘手術(shù)療效評(píng)估及結(jié)腸粘膜5-HT、TRPA1與TRPV1表達(dá)變化研究[D];第三軍醫(yī)大學(xué);2015年

2 鄧輝;腸道亞健康人群結(jié)腸粘膜蛋白質(zhì)組學(xué)研究[D];中南大學(xué);2011年

3 鄭連鵬;轉(zhuǎn)化生長(zhǎng)因子-β及其亞型在潰瘍性結(jié)腸炎患者結(jié)腸粘膜中的表達(dá)[D];天津醫(yī)科大學(xué);2009年

4 陳文華;姜黃水醇提取液對(duì)冰乙酸損傷性潰瘍性結(jié)腸炎大鼠結(jié)腸粘膜保護(hù)作用及機(jī)制研究[D];南昌大學(xué);2011年

5 張志會(huì);5-LOX、iNOS在潰瘍性結(jié)腸炎患者結(jié)腸粘膜中的表達(dá)及其相關(guān)性探討[D];山西醫(yī)科大學(xué);2012年

6 趙曉軍;潰瘍性結(jié)腸炎患者結(jié)腸粘膜中γ-谷胺酰半胱氨酸合成酶的表達(dá)及意義[D];中國(guó)人民解放軍軍醫(yī)進(jìn)修學(xué)院;2008年

7 李新軍;PDIA3對(duì)結(jié)腸粘膜上皮細(xì)胞增殖和凋亡影響的實(shí)驗(yàn)研究[D];暨南大學(xué);2013年

8 鞠輝;感染后IBS患者結(jié)腸粘膜SP與IL-2、IFN-γ表達(dá)的相關(guān)性研究[D];青島大學(xué);2006年

9 葛宇黎;潰瘍性結(jié)腸炎患者結(jié)腸粘膜TNF-α、ICAM-1及CD44s的表達(dá)[D];山西醫(yī)科大學(xué);2004年

10 趙志忠;腸易激綜合征結(jié)腸粘膜AQP8表達(dá)與VIP、SS的表達(dá)研究[D];山西醫(yī)科大學(xué);2008年

本文編號(hào)：2148716